Cypress Pharmaceutical, Inc. v. Tiber Laboratories, LLC

504 F. Supp. 2d 129, 2007 U.S. Dist. LEXIS 52454, 2007 WL 2071814
CourtDistrict Court, S.D. Mississippi
DecidedJuly 19, 2007
DocketCivil Action 3:07CV108TSL-JCS
StatusPublished
Cited by2 cases

This text of 504 F. Supp. 2d 129 (Cypress Pharmaceutical, Inc. v. Tiber Laboratories, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cypress Pharmaceutical, Inc. v. Tiber Laboratories, LLC, 504 F. Supp. 2d 129, 2007 U.S. Dist. LEXIS 52454, 2007 WL 2071814 (S.D. Miss. 2007).

Opinion

MEMORANDUM OPINION AND ORDER

TOM S. LEE, District Judge.

This cause is before the court on the motion of defendant Tiber Laboratories, LLC to dismiss pursuant to Rule 12(b)(2) and (3) of the Federal Rules of Civil Procedure for lack of personal jurisdiction and improper venue, or alternatively, to transfer pursuant to 28 U.S.C. § 1404(a). Plaintiff Cypress Pharmaceutical, Inc. has responded in opposition to the motion and the court, having considered the memoran-da of authorities, together with attachments, submitted by the parties, concludes that it lacks personal jurisdiction over Tiber. Consequently, the case will be transferred to the United States District Court for the Northern District of Georgia.

Plaintiff Cypress Pharmaceutical, Inc. (Cypress), a Mississippi corporation with its principal place of business in Madison, Mississippi, is a specialty pharmaceutical company engaged in the business of developing, marketing and distributing generic prescriptions and over-the-counter pharmaceutical products. Among the products developed and sold by Cypress is Hydro-DP, a prescription cold medicine manufactured for Cypress by Great Southern Laboratories in Houston, Texas. On February 6, 2007, counsel for defendant Tiber Laboratories, LLC (Tiber) wrote to Cypress advising that Tiber had recently acquired Patent No. 6,979,689 (’689) from PediaMed Pharmaceuticals, Inc.; asserting that Endal [¶] syrup, a cough medicine previously marketed throughout the United States by PediaMed, was covered by patent '689; advising that Tiber intended to reintroduce Endal; and expressing a desire to “discuss our exclusive rights to products covered by the '689 patent and your product Hydro-DP and other related products.” The parties had discussions over the next couple of weeks, during which Tiber took the position that Cypress’s Hydro-SP syrup product infringed Tiber’s '689 patent and proposed a possible license arrangement. Cypress maintains that it not only found the terms offered by Tiber unacceptable and rejected the proposal, but specifically questioned the validity of the '689 patent. Ultimately, on either February 19 or 20, Tiber’s president informed Cypress that it would file suit if the parties could not agree to enter a licensee agreement and Cypress did not immediately cease its infringing activities. 1

Cypress filed the present declaratory judgment action against Tiber on February 20, seeking a declaration that it has not infringed any valid claims of the '689 patent, it has not actively induced others to infringe the '689 patent, and the claims of the '689 patent are invalid. The following day, February 21, Tiber, at the time unaware of Cypress’s suit, filed its own suit against Cypress and Great Southern in the Northern District of Georgia for infringement of the '689 patent, and sought a temporary restraining order. Cypress promptly moved to dismiss the Georgia action based on the first-filed rule, *132 and Tiber moved to dismiss, transfer or stay this action, contending, first, that this court lacks personal jurisdiction over Tiber, but arguing alternatively, that the case be transferred to Georgia, a more convenient forum, and that the first-filed rule ought not be applied in this case, given the circumstances in which Cypress filed this suit (i.e, having “raced to the courthouse in anticipation of an imminent suit by Tiber”). By memorandum opinion and order dated May 11, 2007, the Georgia District Court transferred the Tiber suit to this court, citing the well-established rule that where it has been determined that there is substantial overlap, “ ‘the court in which an action is first filed is the appropriate court to determine whether subsequently filed cases involving substantially similar issues should proceed.’ ” Cadle Co. v. Whataburger of Alice, Inc., 174 F.3d 599, 606 (5th Cir.1999) (citation omitted); id. at 606 (“[o]nee the likelihood of a substantial overlap between the two suits ha[s] been demonstrated, it [is] was no longer up to the [second filed court] to resolve the question of whether both should be allowed to proceed.’ ”). See Tiber Laboratories, LLC v. Cypress Pharmaceuticals, Inc., Civil Action No. 2:07-CV-0014-RWS (N.D.Ga. May 11, 2007). The Tiber case, assigned Civil Action No. 3:07CV299, has since been consolidated with this case by agreed order dated July 3, 2007. 2

In patent infringement actions, personal jurisdiction is governed by Federal Circuit law. Silent Drive, Inc. v. Strong Indus., 326 F.3d 1194 (Fed.Cir.2003). Under Federal Circuit precedent, a district court may properly exercise personal jurisdiction over a non-consenting out-of-state defendant if a two-step inquiry is satisfied: “First, the party must be amenable to service of process under the appropriate state long-arm statute. Second, the culmination of the party’s activities within the forum state must satisfy the minimum contacts requirement of the due process clause.” Hildebrand v. Steck Mfg. Co., Inc., 279 F.3d 1351, 1354 (Fed.Cir.2002) (citations omitted). 3

Under Mississippi’s long-arm statute, courts of this state may exercise personal jurisdiction over a nonresident defendant if the defendant has entered a contract with a Mississippi resident to be performed in Mississippi, or has committed a tort in Mississippi, or is conducting business in Mississippi. 4 Cypress does not contend *133 that Tiber has committed a tort in Mississippi or entered a contract with a resident to be performed here. Instead, it relies exclusively on the “doing business” prong of the long arm statute in support of its assertion of jurisdiction.

The general requirements for jurisdiction under the “doing business prong” of the Mississippi long-arm statute are that: “(1) the nonresident ... must purposefully do some act or consummate a transaction in Mississippi; (2) the cause of action must either arise from or be connected with the act or transaction; and (3) the assumption of jurisdiction by Mississippi must not offend traditional notions of fair play and substantial justice.” Internet Doorway, Inc. v. Parks, 138 F.Supp.2d 773, 775 (S.D.Miss.2001) (citing Gross v. Chevrolet Country, Inc., 655 So.2d 873, 877 (Miss.1995)). Under the statute, one is “deemed to be doing business” if he “perform [s] any character of work or service in this state.” Miss.Code Ann. § 13-3-57. See Coats v. Penrod Drilling Corp., 5 F.3d 877, 882 (5th Cir.1993).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Haas Outdoors, Inc. v. Dryshod Int'l, LLC
347 F. Supp. 3d 266 (N.D. Mississippi, 2018)
Tiber Laboratories, LLC v. Hawthorn Pharmaceuticals, Inc.
527 F. Supp. 2d 1373 (N.D. Georgia, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
504 F. Supp. 2d 129, 2007 U.S. Dist. LEXIS 52454, 2007 WL 2071814, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cypress-pharmaceutical-inc-v-tiber-laboratories-llc-mssd-2007.